Which dressings reduce inflammation and improve venous leg ulcer healing

被引:16
作者
Raffetto, Joseph D. [1 ,2 ,3 ]
机构
[1] VA Boston Healthcare Syst, Div Vasc Surg, West Roxbury, MA USA
[2] Brigham & Womens Hosp, Div Vasc & Endovasc Surg, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
关键词
Venous leg ulcer; inflammation; venous hypertension; wound care; leukocytes; macrophage; fibroblasts; adhesions molecules; selectins; chemokines; growth factors; proteases; proteinases; matrix metalloproteinases; compression; biologic skin substitutes; extracellular matrix; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; LOCAL-MANAGEMENT; THERAPY; MATRIX; KERATINOCYTES; GUIDELINES; EFFICACY;
D O I
10.1177/0268355514529225
中图分类号
R61 [外科手术学];
学科分类号
摘要
Chronic venous leg ulcers (VLU) affect around 1% of the adult population in the Western world. The impact of VLU is both social and economic, with significant expenditures on active venous ulcers to provide medical treatment and eventual healing. At the core of VLU is venous hypertension which affects the venous macrocirculation. The changes incurred in venous hemodynamics leads to microcirculatory changes affecting the postcapillary venule and surrounding tissues. Inflammation by leukocytes affecting the venous endothelium, promotes a complex cascade and activation of adhesion molecules expression, chemokines and cytokines released, altered growth factor responses, and activation of protease (e.g. tPA) and proteinase (e.g. MMPs) activity that causes dysregulation and compromise of tissue integrity with eventual dermal damage and ulcer development. A critical component to treating VLU is correcting the abnormal venous hemodynamics and compression therapy. Unfortunately, VLU recurrence ranges between 30-70%, and other modalities in therapy along with compression are required. The goal for adjuvant products is to restore the balance from an inflammatory chronic wound to that of a reparative wound that will promote provisional matrix and epithelialization. There are many products on the market that can be used as adjuvant to compression therapy, but it must be recognized that there is a paucity of clinical trials that have evaluated the clinical effectiveness of specific products with clearly defined end points, and most importantly a healed VLU with a low recurrence rate. This review will discuss the fundamentals of VLU inflammation, and evaluate the available literature that may have benefit in reducing inflammation and lead to effective VLU healing.
引用
收藏
页码:157 / 164
页数:8
相关论文
共 35 条
[1]   Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy [J].
Beidler, Stephanie K. ;
Douillet, Christelle D. ;
Berndt, Daniel F. ;
Keagy, Blair A. ;
Rich, Prestort B. ;
Marston, William A. .
JOURNAL OF VASCULAR SURGERY, 2009, 49 (04) :1013-1020
[2]   Effect of healing on the expression of transforming growth factor βs and their receptors in chronic venous leg ulcers [J].
Cowin, AJ ;
Hatzirodos, N ;
Holding, CA ;
Dunaiski, V ;
Harries, RH ;
Rayner, TE ;
Fitridge, R ;
Cooter, RD ;
Schultz, GS ;
Belford, DA .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (05) :1282-1289
[3]   Randomized, double-blind, placebo-controlled, dose-ranging study of granulocyte-macrophage colony stimulating factor in patients with chronic venous leg ulcers [J].
da Costa, RM ;
Jesus, FMR ;
Aniceto, C ;
Mendes, M .
WOUND REPAIR AND REGENERATION, 1999, 7 (01) :17-25
[4]  
Da Silva A, 1992, Phlebologie, V45, P439
[5]   Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers [J].
Drinkwater, SL ;
Burnand, KG ;
Ding, R ;
Smith, A .
JOURNAL OF VASCULAR SURGERY, 2003, 38 (05) :1106-1112
[6]   Venous ulcers [J].
Etufugh, Chukwuemeka N. ;
Phillips, Tania J. .
CLINICS IN DERMATOLOGY, 2007, 25 (01) :121-130
[7]   TOPICAL USE OF HUMAN RECOMBINANT EPIDERMAL GROWTH-FACTOR (H-EGF) IN VENOUS ULCERS [J].
FALANGA, V ;
EAGLSTEIN, WH ;
BUCALO, B ;
KATZ, MH ;
HARRIS, B ;
CARSON, P .
JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, 1992, 18 (07) :604-606
[8]   A bilayered living skin construct (APLIGRAF®) accelerates complete closure of hard-to-heal venous ulcers [J].
Falanga, V ;
Sabolinski, M .
WOUND REPAIR AND REGENERATION, 1999, 7 (04) :201-207
[9]  
Hankin Cheryl S, 2012, J Manag Care Pharm, V18, P375
[10]   A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers [J].
Harding, Keith ;
Sumner, Michael ;
Cardinal, Matthew .
INTERNATIONAL WOUND JOURNAL, 2013, 10 (02) :132-137